Psoriasis Trial, Recruiting NCT07582783 Sponsor: Janssen Research & Development, LLC Condition: Psoriasis
Back to Psoriasis

Psoriasis Trial, Recruiting

NCT07582783
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with moderate-to-severe plaque psoriasis
  • People who are willing and able to sign a consent form allowing the trial site to verify their health information as required by local rules
  • People who can read, understand, and fill in patient questionnaires in their local language, and are able to complete all required questionnaires throughout the trial
  • People who have never previously been treated with a biological therapy, including the medication guselkumab (sometimes called "bio-naive")
  • People whose doctor has decided to treat them with guselkumab for an approved medical reason

Who may not be able to join:

  • People for whom guselkumab is medically unsuitable according to the most current approved prescribing information for this medication
  • People who are pregnant or currently breastfeeding
  • People who have taken part in another clinical trial involving an experimental treatment within the last 30 days before their first dose of guselkumab in this study
  • People who are currently enrolled in another observational study that is sponsored or managed by a Johnson & Johnson company

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Johnson & Johnson Romania SRL Clinical Trial, Johnson & Johnson Romania SRL

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 May 2026
Est. completion
15 September 2028

Where this trial is recruiting

🇷🇴 Romania

Primary endpoints

Time to Guselkumab Discontinuation Throughout 2 Years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov